β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Open accessThe DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index; 55 of the 76 sources its claims cite were checked for support.
Abstract
OBJECTIVE: This article examines the foundation of β-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS: A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS: The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions. CONCLUSIONS: β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to (1) impact the natural history of β-cell failure; (2) identify and characterize genetic loci for T2D; (3) target β-cell signaling, metabolic, and genetic pathways to improve function/mass; (4) develop alternative sources of β-cells for cell-based therapy; (5) focus on metabolic environment to provide indirect benefit to β-cells; (6) improve understanding of the physiology of responses to bypass surgery; and (7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.
Overview
CoChat Summary
TL;DR
This review/consensus report from an international expert meeting argues that progressive β-cell failure is central to type 2 diabetes, involving genetic/epigenetic changes and multiple stressors that lead to dysfunction, dedifferentiation, and death. It concludes existing therapies can improve β-cell function temporarily but generally do not arrest or reverse progression, with possible exception of gastric bypass, and identifies noninvasive β-cell mass measurement and stage-specific/combinatorial interventions as key research needs.
Key findings
- Over 60 genetic loci have been convincingly associated with T2D, the great majority involved in some way in β-cell biology, but these variants explain only a small proportion of total genetic risk; approximately 50% of T2D-associated SNPs introduce or remove a CpG site, suggesting genetic-epigenetic interactions.
- β-cell mass in T2D varies and overlaps with normal individuals, although current data suggest a 20–60% reduction; human β-cell mass varies three- to fivefold unrelated to age or BMI, and insulin sensitivity may vary as much as 10-fold. β-cell function and mass declines are not well correlated, while deteriorating β-cell function is tightly correlated with climbing glucose levels.
- Multiple stressors are implicated: ER stress, metabolic/oxidative stress, amyloid/IAPP oligomers, islet inflammation (IL-1β antagonism can preserve some β-cell functional mass), and disrupted islet integrity. β-cell dedifferentiation has regained favor, and residual β-cells remain even in late disease.
- Interventions show temporary β-cell functional improvement: in the DPP, greater baseline β-cell function and insulin sensitivity independently contributed to restoration of normal glucose tolerance; TZDs improved the oral disposition index; GLP-1–based therapies improve function during treatment but no meaningful persistent change follows withdrawal; RYGB produces disease remission in at least 80% of patients, with duration of diabetes and insulin use before surgery as strongest predictors.
Methods
- Design: narrative review/consensus report from the October 2013 meeting “Beta Cell Failure in Type 2 Diabetes,” cosponsored by the Endocrine Society and the American Diabetes Association, assembling international experts to review the state of the science and identify research needs.
- Data/sample: no primary experimental sample; synthesis of published human and animal studies, including genetics, epigenetics, islet biology, clinical trials, and surgical interventions.
- Analysis: expert discussion and narrative synthesis; future research goals are presented in Table 1 (not included in the provided text).
Limitations
- Stated: studies of epigenetics in T2D are severely limited by the small number of islets available from patients with T2D and by difficulty separating cause and effect in hyperglycemia; human β-cell mass measurement relies entirely on postmortem, cross-sectional assessments, and histomorphometric measurement of β-cell area, volume, and mass is often imprecisely defined and complicated by technical inconsistencies.
- Stated: no study has established whether one pathogenic pathway dominates or can serve as a single major target; durability of β-cell functional improvements following therapy withdrawal remains challenging, and whether earlier intervention can alter the natural history of β-cell failure is unknown.
- Evident from the text: as an expert consensus/narrative review, it does not describe a systematic search strategy or quantitative meta-analysis, and many cited mechanisms and genetic associations remain uncertain or require human validation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
35 Valid · 6 Not valid · 7 Not checked · 26 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“At the time of writing, over 60 genetic loci have been convincingly associated with T2D”
What the sources say
- Disputedcites [8] Voight, 2010, Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis, Nat Genet sourceExperimental — accuracy not yet measured
The Discussion states that the number of confirmed T2D loci stood at 38 when the source paper was written, not over 60. The paper cannot establish a later count at the citing document’s time of writing. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [9] Rosengren, 2012, Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes, Diabetes sourceExperimental — accuracy not yet measured
The source paper's Abstract says recent genome-wide association studies had identified close to 50 loci associated with T2D risk, not over 60. Its count is contrary to the number attributed to it. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
What the sources say
- Not checked — no full text of the sourcecites [71] Fehse, 2005, Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes, J Clin Endocrinol Metab source
- Disputedcites [73] Bunck, 2011, Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
The Results (Measures of β-cell function; page unavailable) report a sustained improvement in the disposition index four weeks after exenatide withdrawal, contrary to the categorical claim that none of these agents produced a persistent change. The Conclusions call the effect small and note that it was not enough to sustain glycemic control; the Results (Glycemic control; page unavailable) report that HbA1c and fasting glucose returned to pretreatment values after 12 weeks off treatment. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“further suggest that hyperglycemia alters DNA methylation of PDX1 and INS ( 22 – 25 ).”
What the sources say
- Partly supportedcites [22] Yang, 2012, Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes, Mol Endocrinol sourceExperimental — accuracy not yet measured
The 'Impact of hyperglycemia on DNA methylation of PDX-1' section (page not supplied) reports that HbA1c correlated with PDX-1 methylation in human islets and that high glucose nominally increased Pdx-1 methylation in rat β-cells. The paper does not present a corresponding finding that hyperglycemia alters INS methylation; its Discussion mentions insulin-promoter methylation in patients with type 2 diabetes as a finding from earlier work. (LLM, conf=0.85)
- Supportedcites [23] Yang, 2011, Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets, Diabetologia source
The Discussion reports that 72 hours of hyperglycaemia increased insulin-promoter DNA methylation in clonal rat beta cells, supporting the INS part for which this paper is cited. PDX1 appears only as an insulin-promoter binding-site label in the Results figure caption; this paper is not the source for that part of the multi-citation sentence. (LLM, conf=0.90)
- Could not verifycites [24] Ling, 2008, Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion, Diabetologia sourceExperimental — accuracy not yet measured
The Methods and Results (page not available) examine DNA methylation of PPARGC1A and report higher methylation in diabetic than non-diabetic islets. Searches for PDX1, INS, and hyperglycemia-related methylation found no passage addressing whether hyperglycemia alters methylation of PDX1 or INS. (LLM, conf=0.74)
- Disputedcites [25] Volkmar, 2012, DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients, EMBO J sourceExperimental — accuracy not yet measured
The Results section, “Differential DNA methylation observed in T2D islets is not inducible by high glucose” (page unavailable), reports no significant methylation changes at the tested sites after high-glucose exposure and concludes that T2D-related methylation differences are probably not secondary to hyperglycaemia. It does not report a high-glucose effect on PDX1 or INS specifically, so its findings do not establish the opposite for those two genes; nevertheless, the paper’s stated conclusion runs contrary to the claim attributed to it. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“knockout of miR-375 promotes progressive hyperglycemia in mouse models due to decreased insulin content and progressive loss of β-cell mass ( 32 ).”
What the sources say
- Disputedcites [32] Poy, 2009, miR-375 maintains normal pancreatic alpha- and beta-cell mass, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The Results report hyperglycemia and reduced β-cell mass in miR-375 knockout mice, but the measured mass deficit was 38% at 3 weeks and 31% at 10 weeks, not a progressive loss. The Discussion explicitly attributes their hyperglycemia primarily to an α-cell defect and says the reduction in β-cell mass is unlikely to explain it; plasma insulin was unchanged in these mice. Insulin-deficient diabetes was reported for the separate obese 375/ob model. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Powerful evidence for a genetic component to T2D ( 1 ) has driven extensive efforts to identify genetic variants contributing to risk.”
What the sources say
- Supportedcites [1] Meigs, 2000, Parental transmission of type 2 diabetes: the Framingham Offspring Study, Diabetes source
The paper's Abstract calls type 2 diabetes heritable and says twin concordance, population patterns, and family aggregation support genetic determinants. Its Discussion also considers paternal genetic factors in diabetes risk. (LLM, conf=0.93)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
38 more claims · 21 with their cited sources checked
Create a free account to see all 74 claims and every source verdict.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inflammation can be a mediator of insulin resistance and beta-cell damage by high glucose, fatty acids, or adipokines released from adipose tissues [37–39].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [38]
Experimental — accuracy not yet measured
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336 · cited 1×
“case, these variants explain only a small proportion of total genetic risk (11).”
Backgroundβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737 · cited 1×
“esis (46), results from a janitorial macrophage infiltration to clear damaged islet b-cells and/or an innate”
BackgroundA pancreatic islet-specific microRNA regulates insulin secretion
Poy, M. N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P. E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004) · Nature · doi:10.1038/nature03076 · Cited by 2,102
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis
The MAGIC investigators, Voight, B. F., The GIANT Consortium, Scott, L. J., Steinthorsdottir, V., Morris, A. P., Dina, C., Welch, R. P., Zeggini, E., Huth, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.609 · Cited by 1,761
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Self-citationMasters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 1×
“levels that allow proapoptotic IAPP oligomers to form (44) that induce interleukin (IL)-1b release to recruit macrophages and enhance local islet inflammation (45).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 4×
“GLP-1based therapies magnify glucose-stimulated insulin secretion, as seen with significantly improved β-cell function in T2D following short-term infusions of GLP-1 (68, 69) and longer-”
Influential
Cited by
Items 201–300 of 462
DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis
Padron, S., Rogers, E., Beckler, M. D., & Kesselman, M. M. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-228981 · Cited by 21
Luo, J., Zheng, M., Jiang, B., Li, C., Guo, S., Wang, L., Li, X., Yu, R., & Shi, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15195 · Cited by 21
“In T2DM patients, beta cell failure occurs as a result of de-differentiation, which results in the decrease in beta cell numbers (Halban et al., 2014).”
BackgroundInterorgan crosstalk in pancreatic islet function and pathology
Evans, R. M., & Wei, Z. (2022) · FEBS Letters · doi:10.1002/1873-3468.14282 · Cited by 22
Rohli, K. E., Boyer, C. K., Bearrows, S. C., Moyer, M. R., Elison, W. S., Bauchle, C. J., Blom, S. E., Yu, C.-L., Pope, M. R., 张建朝, et al. (2022) · Function · doi:10.1093/function/zqac051 · Cited by 24
Min, K. W., Ku, B. J., Lee, J. H., Kim, M., Ahn, K. J., Lee, M., Kokubo, S., Yoshida, S., Cho, H.-J., & Soo, B. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.2.135 · Cited by 20
“Because impaired insulin secretion and increased insulin resistance are the main pathological features of type 2 diabetes mellitus [5], and Asian patients have the propensity to develop diabetes with greater insulin resistance and reduced insulin secretion compared with white patients [6,7], combination therapy with o…”
BackgroundSung, H. H., Park, C.-E., Gi, M. Y., Cha, J. A., Moon, A. E., Kang, J. K., Seong, J.-M., Lee, J. H., & Yoon, H. J. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0517 · Cited by 20
“Some studies have emphasized that physicians should aim to maintain normal beta-cell mass and function for prevention and treatment of diabetes; beta-cell failure is central to the development and progression of DM [43, 44].”
BackgroundBraving the Element: Pancreatic β-Cell Dysfunction and Adaptation in Response to Arsenic Exposure
Carmean, C. M., & Seino, S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00344 · Cited by 20
A Comprehensive Review on Preclinical Diabetic Models
Shakya, A., Chaudary, S. K., Garabadu, D., Bhat, H. R., Kakoti, B. B., & Ghosh, S. K. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190510112035 · Cited by 17
Boyer, C. K., Bauchle, C. J., Zhang, J., Wang, Y., & Stephens, S. B. (2023) · Scientific Reports · doi:10.1038/s41598-023-32322-z · Cited by 21
McCarthy, K. J., Liu, S. H., Huynh, M., Kennedy, J., Chan, H. T., Mayer, V., Vieira, L., Tabaei, B. P., Howell, F., Lee, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1676 · Cited by 20
Serum fetuin-A levels in obese and non-obese subjects with and without type 2 diabetes mellitus
Zhou, Z., Ju, H., Sun, M., Chen, H., Fu, Q.-P., & Jiang, D. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.11.023 · Cited by 19
Li, Y., Yang, X., Gu, H., Snellingen, T., Liu, X.-P., & Liu, N. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.03.21 · Cited by 17
Landgraf, W., Owens, D. R., Frier, B. M., Zhang, M., & Bolli, G. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13897 · Cited by 22
Sustained hyperglycemia specifically targets translation of mRNAs for insulin secretion
(2023) · doi:10.1172/jci173280 · Cited by 19
Stem cell therapy for insulin-dependent diabetes: Are we still on the road?
Yang, L., Hu, Z.-M., Jiang, F.-X., & Wang, W. (2022) · World Journal of Stem Cells · doi:10.4252/wjsc.v14.i7.503 · Cited by 14
Adami, G. F., Camerini, G. B., Papadia, F. S., Catalano, M., Carlini, F., Cordera, R., & Scopinaro, N. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3511-6 · Cited by 19
Cereulide food toxin, beta cell function and diabetes: Facts and hypotheses
Vangoitsenhoven, R., Maris, M., Overbergh, L., Loco, J. V., Mathieu, C., & der Schueren, B. V. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.029 · Cited by 18
Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
van Raalte, D. H., & Verchere, C. B. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.04.009 · Cited by 19
Ding, L., Fan, Y., He, J., Wang, R., He, Q., Cui, J., Ma, Z., Zheng, F., Gao, H., Dai, C., et al. (2021) · Obesity · doi:10.1002/oby.23151 · Cited by 17
Zhang, L., He, S., Liu, L., & Huang, J. (2024) · Phytotherapy Research · doi:10.1002/ptr.8229 · Cited by 20
“However, over time, β -cell compensation in a subset of individuals cannot be sustained, and β cells become dysfunctional, resulting in ER stress, mitochondrial dysfunction, oxidative stress, and inflammation (Halban et al., 2014).”
Shteinfer‐Kuzmine, A., Santhanam, M., & Shoshan‐Barmatz, V. (2024) · Biomolecules · doi:10.3390/biom14091139 · Cited by 20
“In response to insulin resistance, β -cells increase insulin production, which gradually leads to their destruction, as well as to hyperglycemia and eventual insulin dependence [128].”
BackgroundScopinaro, N., Camerini, G. B., Papadia, F. S., Andraghetti, G., Cordera, R., & Adami, G. F. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2015.12.011 · Cited by 16
“Furthermore, AIR and IGI data at 5 years after BPD are similar to that observed at 1 year, without the progressive failure over time of β-cell function that characterizes the natural history of T2D [26,29].”
BackgroundCraig, S. L., Gault, V. A., McClean, S., Hamscher, G., & Irwin, N. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110523 · Cited by 16
Selectively Bred Diabetes Models: GK Rats, NSY Mice, and ON Mice
Nagao, M., Esguerra, J. L. S., Wendt, A., Asai, A., Sugihara, H., Oikawa, S., & Eliasson, L. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0385-7_3 · Cited by 16
Fushimi, Y., Obata, A., Sanada, J., Nogami, Y., Ikeda, T., Yamasaki, Y., Obata, Y., Shimoda, M., Nakanishi, S., Mune, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94896-w · Cited by 18
Teitelman, G. (2019) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155419831641 · Cited by 19
Jetton, T. L., Flores-Bringas, P., Leahy, J. L., & Gupta, D. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101250 · Cited by 16
Diabetes mellitus: interdisciplinary medical, surgical and psychological therapeutic approach
Socea, B., Silaghi, A. M., Rebegea, L. F., Bălan, D. G., Bălălău, C., Ţenea-Cojan, T. Ş., Mihai, D. A., & Păunică, I. (2023) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1445 · Cited by 18
Kubo, F., Miyatsuka, T., Sasaki, S., Takahara, M., Yamamoto, Y., Shimo, N., Watada, H., Kaneto, H., GANNON, M. A., Matsuoka, T., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.177 · Cited by 18
From bariatric to metabolic surgery: Looking for a “disease modifier” surgery for type 2 diabetes
Cordera, R., & Adami, G. F. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i2.27 · Cited by 19
Admin, A., Li, R., Kondegowda, N. G., Filipowska, J., Hampton, R. F., Leblanc, S., García-Ocaña, A., & Vasavada, R. C. (2020) · Diabetes · doi:10.2337/db19-0909 · Cited by 17
Xu, Y., Zhou, Y., Liu, J., Wang, C., Qu, Z., Wei, Z., & Zhou, D. (2020) · Medicine · doi:10.1097/md.0000000000023672 · Cited by 18
Paul, A., Azhar, S., Das, P. N., Bairagi, N., & Chatterjee, S. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105365 · Cited by 16
Kumar, P., Ram, H., Kala, C., Kashyap, P., Singh, G., Agnihotri, C., Singh, B. P., Kumar, A., & Panwar, A. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2103029 · Cited by 15
“Type 2 diabetes is a complex metabolic disease characterized by altered insulin sensitivity and impaired insulin secretion (Halban et al., 2014).”
BackgroundBeta Cell Imaging—From Pre-Clinical Validation to First in Man Testing
Demine, S., Schulte, M. I., Territo, P. R., & Eizirik, D. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197274 · Cited by 15
“Sci. 2020, 21, 7274 2 of 29 T2D rely on lifestyle changes (weight loss and exercise) and the use of drugs stimulating the release of endogenous insulin and/or increasing the peripheral sensitivity to this hormone, with the eventual addition of exogenous insulin [9].”
BackgroundInfluentialBułdak, Ł., Machnik, G., Skudrzyk, E., Bołdys, A., Maligłówka, M., Kosowski, M., Basiak, M., Bułdak, R. J., & Okopień, B. (2022) · Journal of Applied Biomedicine · doi:10.32725/jab.2022.015 · Cited by 15
Characterization of Novel Nonobese Type 2 Diabetes Rat Model with Enlarged Kidneys
Domon, A., Katayama, K., Tochigi, Y., & Suzuki, H. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8153140 · Cited by 14
HIF-2α Preserves Mitochondrial Activity and Glucose Sensing in Compensating β-Cells in Obesity
Moon, J.-S., Riopel, M., Seo, J. B., Herrero-Aguayo, V., Isaac, R., & Lee, Y. S. (2022) · Diabetes · doi:10.2337/db21-0736 · Cited by 13
A metabolic redox relay supports ER proinsulin export in pancreatic islet β cells
Rohli, K. E., Stubbe, N. J., Walker, E. M., Pearson, G. L., Soleimanpour, S. A., & Stephens, S. B. (2024) · JCI Insight · doi:10.1172/jci.insight.178725 · Cited by 20
“In T2D, the deterioration of β cell function is a defining feature of the transition from insulin resistance to overt diabetes (62, 63).”
Dalle, S., & Abderrahmani, A. (2024) · Cells · doi:10.3390/cells13151244 · Cited by 18
Nolan, C. J., & Delghingaro‐Augusto, V. (2016) · Diabetes · doi:10.2337/dbi15-0020 · Cited by 13
Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c
Abdul-Ghani, M. A., Migahid, O., Megahed, A., DeFronzo, R. A., Zirie, M. A., & Jayyousi, A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3423 · Cited by 15
Novel Strategies for Inducing Glycemic Remission during the Honeymoon Phase of Type 2 Diabetes
Retnakaran, R. R. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.08.007 · Cited by 16
The β-cell effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review
Carnovale, C., Dassano, A., Mosini, G., Mazhar, F., D’Addio, F., Pozzi, M., Radice, S., Fiorina, P., & Clementi, E. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01370-1 · Cited by 13
Inaishi, J., Saisho, Y., Hirakawa, Y., Yoshida, D., Hata, J., Mukai, N., Watanabe, Y., Oda, Y., Itoh, H., & Ninomiya, T. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13232 · Cited by 12
Liu, L., Cheng, Y. T., Xu, A., & Cheung, B. M. Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02003-2 · Cited by 12
Transcriptional Regulation of the Pancreatic Islet: Implications for Islet Function
Stitzel, M. L., Kycia, I., Kursawe, R., & Ucar, D. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0635-0 · Cited by 13
Characterization of pioglitazone cyclodextrin complexes: Molecular modeling to in vivo evaluation
Pissurlenkar, R. R. S., Nagarsenker, M. S., Bramhane, D. M., Kulkarni, P., Martis, E. A. F., & Coutinho, E. C. (2015) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.171680 · Cited by 13
Wang, T., Zheng, W., Huang, W., Zhang, L., Tian, Z., Zhang, T., Qi, Y., & Li, G. (2019) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14009 · Cited by 12
Nema, P., Asati, V., Kendya, P., Gupta, T., Agarwal, S., Kori, S. K., Kashaw, V., Iyer, A. K., & Kashaw, S. K. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230302140658 · Cited by 12
PHLPP phosphatases as a therapeutic target in insulin resistance-related diseases
Hribal, M. L., Mancuso, E., Spiga, R., Mannino, G. C., Fiorentino, T. V., Andreozzi, F., & Sesti, G. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1130822 · Cited by 13
“[87] Our data, as well as previous studies demonstrating”
ResultShabrawy, A. M. E., Elbana, K. A., & Abdelsalam, N. M. (2019) · Diabetes & metabolic syndrome · doi:10.1016/j.dsx.2019.04.044 · Cited by 13
Down Syndrome-Associated Diabetes Is Not Due To a Congenital Deficiency in β Cells
Butler, A., Sacks, W. L., Rizza, R., & Butler, P. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1042 · Cited by 9
Pancreatic 18F-FDG uptake is increased in type 2 diabetes patients compared to non-diabetic controls
Bakker, G. J., Vanbellinghen, M. C., Scheithauer, T. P. M., Verchere, C. B., Stroes, E. S. G., Timmers, N. K. L. M., Herrema, H., Nieuwdorp, M., Verberne, H. J., & van Raalte, D. H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213202 · Cited by 12
The anterior chamber of the eye technology and its anatomical, optical, and immunological bases
Yang, S.-N., Shi, Y., & Berggren, P. (2024) · Physiological Reviews · doi:10.1152/physrev.00024.2023 · Cited by 14
Liu, J.-J., Gurung, R. L., Liu, S., Yiamunaa, M., Lee, J., Ang, K., Tavintharan, S., Tang, W. E., Sum, C. F., & Lim, S. C. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101238 · Cited by 12
Munder, A., Israel, L. L., Kahremany, S., Binyamini, R. B.-S., Zhang, C., Kolitz‐Domb, M., Viskind, O., Levine, A., Senderowitz, H., Chessler, S. D., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b10568 · Cited by 11
TERT and Akt Are Involved in the Par-4-Dependent Apoptosis of Islet β Cells in Type 2 Diabetes
Chen, L., Wu, Q., XiaoTian, L., Yang, M., XiaGuang, G., Leng, W., Liang, Z., Ling, Z., Yang, G., & Chen, B. (2018) · Journal of Diabetes Research · doi:10.1155/2018/7653904 · Cited by 11
Xu, H., Zhang, Y., Xu, W., Chen, L., Zhang, M., Su, H., Cheng, Y., Zhao, N., Xu, D., & Qin, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.05.003 · Cited by 13
Effects of subchronic acrylamide treatment on the endocrine pancreas of juvenile male Wistar rats
Stošić, M., Matavulj, M., & Marković, J. (2018) · Biotechnic & Histochemistry · doi:10.1080/10520295.2017.1393562 · Cited by 10
“A similar trend of decreased β-cell mass has been reported for studies of diabetes mellitus in diabetic humans and rats (Karlsson et al. 2000, Szkudelski 2001, Sakuraba et al. 2002, Cnop et al. 2005, Akbarzadeh et al. 2007, Halban et al. 2014, Primoradi et al. 2016).”
BackgroundVerapamil and Its Role in Diabetes
Zimmermann, P., Aberer, F., Eckstein, M. L., Haupt, S., Erlmann, M. P., & Moser, O. (2022) · Diabetology · doi:10.3390/diabetology3030030 · Cited by 13
“Different mechanisms are postulated for β-cell failure as demonstrated especially for T2D individuals [36].”
BackgroundBeta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 16
“Broadly, they encompass genetic and epigenetic factors, 14 de-differentiation of beta-cells, increased apoptosis, metabolic and oxidative stress, and hyperglycemia itself.”
BackgroundJia, H., Liu, Y., & Liu, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1221228 · Cited by 14
Dauriz, M., Trombetta, M., Boselli, L., Santi, L., Brangani, C., Pichiri, I., Bonora, E., & Bonadonna, R. C. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0807-z · Cited by 10
Guglielmi, C., Toro, R. D., Lauria, A., Maurizi, A. R., Fallucca, S., Cappelli, A., Angeletti, S., Lachin, J. M., & Pozzilli, P. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2899 · Cited by 13
“In T2D, the incretin axis may be impaired, and this is attributed to defective gastric inhibitory peptide (GIP) action and/or reduced glucagon‐like peptide‐1 (GLP‐1) secretion.11 On the other hand, inT1D only few data are available, and Kaas et al reported GIP/GLP‐1 reduced response in patients with recent onset T1D.1…”
BackgroundInfluentialXu, M., Hu, H., Deng, D., Chen, M., Xu, Z., & Wang, Y. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12565 · Cited by 11
“β-Cell failure is critical to the development and progression of T2D, and it antedates and predicts diabetes onset and progression.(50) Therefore, further studies are needed to establish the role of E23K polymorphism of KCNJ11 in the mechanisms of insulin secretion and β-cell function during the progression to diabete…”
BackgroundArsenic Exposure and Lifestyle-Related Diseases
Xu, Y., Fu, J., Wang, H. H., Hou, Y., & Pi, J. (2018) · Current topics in environmental health and preventive medicine · doi:10.1007/978-981-13-2565-6_6 · Cited by 13
Wang, J., Liu, W.-J., & Lee, W. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211026391 · Cited by 10
The role of mitochondrial apoptotic pathway in islet amyloid-induced β-cell death
Wong, H. Y., Hui, Q., Hao, Z., Warnock, G. L., Woo, M., Luciani, D. S., & Marzban, L. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111424 · Cited by 13
Prolactin-regulated Pbk is involved in pregnancy-induced β-cell proliferation in mice
Cao, Y., Feng, Z., He, X., Zhang, X., Xing, B., Wu, Y., Hojnacki, T., Katona, B. W., Ma, J., Zhan, X., et al. (2021) · Journal of Endocrinology · doi:10.1530/joe-21-0114 · Cited by 12
Takai, M., Anno, T., Kawasaki, F., Kimura, T., Hirukawa, H., Mune, T., Okimoto, N., Kaku, K., & Kaneto, H. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1053-18 · Cited by 10
“Under diabetic conditions, however, when β-cells are chronically exposed to hyperglycemia, the β-cell function is gradually deteriorated, and β-cells fail to secrete sufficient amounts of insulin (1-6).”
BackgroundEtiologies underlying subtypes of long-standing type 2 diabetes
Bayoumi, R., Farooqi, M. H., Alawadi, F., Hassanein, M. M., Osama, A., Mukhopadhyay, D., Abdul, F., Sulaiman, F., Dsouza, S., Mulla, F., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304036 · Cited by 11
Zhou, Y., Hu, L., Zhuang, R., Song, L., Chang, X., Liu, L., Huang, Y., Zhang, M., Zheng, J., Xu, X., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06459-7 · Cited by 12
Loganadan, N. K., Huri, H. Z., Vethakkan, S. R., & Hussein, Z. B. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0171 · Cited by 12
Wu, L., Lv, Y.-C., Lv, Y., Xiang, S., Zhao, Z., Tang, Z., Ou, L., Yan, B., Xiao, X., Wen, G., et al. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa142 · Cited by 9
Popescu, M., Radivojević, K., Trașcă, D.-M., Văruț, R. M., Enache, I., & Osman, A. (2025) · Pharmaceuticals · doi:10.3390/ph18050682 · Cited by 16
“These disturbances further impair ER calcium handling, amplify pro-apoptotic signaling, degrade proinsulin mRNA, and promote interleukin-1 β (IL-1 β ) release, recruiting macrophages and intensifying local islet inflammation [42].”
InfluentialSuleiman, M., Sawatani, T., Tesi, M., Yi, X., Papadopoulou, T. A., Rufer, C., Lytrivi, M., Bosi, E., Burdet, F., Fantuzzi, F., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads2905 · Cited by 18
Zhou, S.-M., Yao, X.-M., Cheng, Y. M., Xing, Y., Sun, Y., Hua, Q., Wan, S., & Meng, X.-J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24432 · Cited by 8
“This multifactorial process involves various stressors, including but not limited to metabolic and oxidative stress [3,4], altered growth factors [5], immune attacks [6], and circulating hormones [7].”
BackgroundAmeliorative Effects of Essential Oils on Diabetes Mellitus: A Review
Barbhuiya, P. A., Pariong, D., Alam, A. P., Mazumder, T. M. S. R., Sarma, S., Sen, S., & Pathak, M. P. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266314922240822091215 · Cited by 10
Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis
Mezza, T., Moffa, S., Ferraro, P. M., Quero, G., Capece, U., Carfì, A., CEFALO, C. M. A., Cinti, F., Sorice, G. P., Impronta, F., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02804 · Cited by 8
Aoyama, S., Nishida, Y., Fujitani, Y., Fukunaka, A., Miyatsuka, T., Suzuki, L., Himuro, M., Yoshimori, T., & Watada, H. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0326 · Cited by 8
“Insulin resistance, followed by pancreatic beta-cell failure, has been postulated to play a canonical role in the development of type 2 diabetes [2].”
BackgroundYefet, E., Schwartz, N., Sliman, B., & Nachum, Z. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05827-5 · Cited by 8
Kaneto, H., Obata, A., Kimura, T., Shimoda, M., Sanada, J., Fushimi, Y., Katakami, N., Matsuoka, T., & Kaku, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249444 · Cited by 9
Protective effects of Stevia rebaudiana extracts on beta cells in lipotoxic conditions
Bugliani, M., Tavarini, S., Grano, F., Tondi, S., Lacerenza, S., Giusti, L., Ronci, M., Maidecchi, A., Marchetti, P., Tesi, M., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01793-9 · Cited by 9
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac111.81418155 · Cited by 15
STAT3 suppression and β-cell ablation enhance α-to-β reprogramming mediated by Pdx1
Wakabayashi, Y., Miyatsuka, T., Miura, M., Himuro, M., Taguchi, T., Iida, H., Nishida, Y., Fujitani, Y., & Watada, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-25941-5 · Cited by 8
Li, M., Feng, D., Zhang, K., Gao, S., & Lu, J. (2016) · International Journal of Endocrinology · doi:10.1155/2016/4740678 · Cited by 7
Yan, Z., Shyr, Z. A., Fortunato, M., Welscher, A., Alisio, M., Martino, M. R., Finck, B. N., Conway, H., & Remedi, M. S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13423 · Cited by 8
Renalase inhibition defends against acute and chronic β cell stress by regulating cell metabolism
MacDonald, T. L., Ryback, B. A., Pereira, J. A. D. S., Wei, S., Mendez, B., Cai, E. P., Ishikawa, Y., Arbeau, M., Weir, G. C., Bonner‐Weir, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102115 · Cited by 8
Self-citationTherapeutic effect of Momordica charantia on cardiomyopathy in a diabetic maternal rat model
Elnahas, S. M., Mansour, H. A. E., El-Sawi, M. R., & Abou‐El‐Naga, A. M. (2024) · Journal of Experimental Zoology Part A Ecological and Integrative Physiology · doi:10.1002/jez.2854 · Cited by 7
GLP-1 localisation and proglucagon gene expression in healthy and diabetic mouse ileum
TAŞÇI, S. K., & BİNGÖL, S. A. (2018) · Journal of Veterinary Research · doi:10.2478/jvetres-2018-0033 · Cited by 9
“Diabetes mellitus (DM) is a metabolic disease characterised by hyperglycaemia because of insulin resistance or pancreatic β-cell failure (10).”
BackgroundRepublished: DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis
Padron, S., Rogers, E., Beckler, M. D., & Kesselman, M. M. (2019) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2019.228981rep · Cited by 8
Evaluating the 1-h post-load glucose level to predict future type 2 diabetes
Saunajoki, A., AUVINEN, J. P., Bloigu, A. H., Timonen, M., & Keinanen-Kiukaanniemi, S. M. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108009 · Cited by 7
Trieger, G. W., Pessentheiner, A. R., Purcell, S. C., Green, C. R., DeForest, N., Willert, K., Majithia, A. R., Metallo, C. M., Godula, K., & Gordts, P. L. S. M. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104611 · Cited by 10
“This insulin resistance coincides with the onset of T2D, leading ultimately to beta cell failure (6, 7).”
BackgroundKim, J. L., Gamma, E. F. L., Estabrook, T., Kudrick, N., & Nankova, B. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172789 · Cited by 9
Jung, I., Choi, S., Hong, S. A., Hwang, Y., & KANG, Y. Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-13365-5 · Cited by 7
Discoveries in Pancreatic Physiology and Disease Biology Using Single-Cell RNA Sequencing
Fu, H., Sun, H., Kong, H., Lou, B., Chen, H., Zhou, Y., Huang, C., Qin, L., Shan, Y., & Dai, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.732776 · Cited by 10
“T1DM is caused by the destruction of more than 80% of β-cells and mediated by autoimmunity in the pancreas, while T2DM is caused by the enhancement of insulin resistance, which eventually aggravates the effects of dysfunctional β-cells, rendering the remaining β-cells insufficient to meet the homeostatic needs (Halban…”
BackgroundDelineating mouse β-cell identity during lifetime and in diabetes with a single cell atlasPreprint
Hrovatin, K., Bastidas-Ponce, A., Bakhti, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.22.521557 · Cited by 7
Emerging Roles of Post-Translational Modifications in Metabolic Homeostasis and Type 2 Diabetes
Kim, Y. K., & Kim, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311552 · Cited by 9
“This failure reflects a combination of reduced beta cell mass, impaired stimulus–secretion coupling, loss of mature identity, and increased vulnerability to stress [33,34].”
Immunometabolism in obesity: Understanding the beneficial and detrimental roles of inflammation
Lee, Y. S. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003620 · Cited by 13
Metadata
- Authors
- Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C.
- Affiliations
- University of Geneva (CH)
- University of Chicago (US)
- Wake Forest University (US)
- Albert Einstein College of Medicine (US)
- Lund University (SE)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Columbia University (US)
- Joslin Diabetes Center (US)
- Corresponding author
- Halban, Philippe A.
- Polonsky, Kenneth S.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-05-10
- Volume
- 37
- Issue
- 6
- Pages
- 1751-1758
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4179518
- OpenAlex
- W2142418958
- Semantic Scholar
- b30b808a69da53c538eed4ffb6c8ae812e4bfe16
- Cited by
- 460
- References
- 91
- Citations by year
- 2026: 23 · 2025: 27 · 2024: 30 · 2023: 38 · 2022: 41 · 2021: 37 · 2020: 49 · 2019: 50 · 2018: 46 · 2017: 57 · 2016: 29 · 2015: 30 · 2014: 3
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- Sanofi
- University of Pennsylvania
- University of Washington
- University of Exeter
- Vrije Universiteit Amsterdam
- Lunds Universitet
- Novo Nordisk
- Università di Pisa
- Novo Nordisk Fonden (NNF11OC1014546)
- National Institutes of Health (UL1TR000430)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082590, P30DK020593, P30DK020595)
- National Center for Advancing Translational Sciences
- Children's Hospital of Pittsburgh
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- beta-cell failure, type 2 diabetes, beta-cell dysfunction, beta-cell mass, genetic susceptibility, diabetes prevention, diabetes treatment, genetic loci, cell therapy, bariatric surgery, circulating factors
- MeSH terms
- Congresses as Topic, Diabetes Mellitus, Type 2, Expert Testimony, Humans, Signal Transduction, Genetic Predisposition to Disease, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.